Papers - FUJIHARA Kazuo
-
The real-world impact of biologics for NMOSD: A retrospective single-center study compared with natural course and conventional treatments in Japanese.
Yamazaki N, Misu T, Matsumoto Y, Takai Y, Namatame C, Ono H, Kaneko K, Nishiyama S, Kuroda H, Takahashi T, Nakashima I, Fujihara K, Aoki M
Mult Scler Relat Disord 92 106176 2024.12
-
Clinical practice guidelines for multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease 2023 in Japan.
Niino M, Isobe N, Araki M, Ohashi T, Okamoto T, Ogino M, Okuno T, Ochi H, Kawachi I, Shimizu Y, Takahashi K, Takeuchi H, Tahara M, Chihara N, Nakashima I, Fukaura H, Misu T, Miyazaki Y, Miyamoto K, Mori M, Kinoshita M, Takai Y, Fujii C, Watanabe M, Fujihara K
Mult Scler Relat Disord 90 105829 2024.10
-
Safety and effectiveness of satralizumab in Japanese patients with neuromyelitis optica spectrum disorder: a 6-month interim analysis of post-marketing surveillance.
Yamamura T, Isobe N, Kawachi I, Nohara C, Miyazaki Y, Tomita M, Tsumuraya T, Yamashita K, Nakahara J, Nakashima I, Fujihara K
Neurol Ther 13 ( 5 ) 1361 - 1383 2024.10
-
Different complement activation patterns following C5 cleavage in MOGAD and AQP4-IgG+NMOSD.
Kaneko K, Kuroda H, Matsumoto Y, Sakamoto N, Yamazaki N, Yamamoto N, Umezawa S, Namatame C, Ono H, Takai Y, Takahashi T, Fujimori J, Nakashima I, Harigaya Y, Lassmann H, Fujihara K, Misu T, Aoki M
Neurol Neuroimmunol Neuroinflamm 11 ( 5 ) e200293 2024.9
-
Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis.
Arnett S, Chew SH, Leitner U, Hor JY, Paul F, Yeaman MR, Levy M, Weinshenker BG, Banwell BL, Fujihara K, Abboud H, Dujmovic Basuroski I, Arrambide G, Neubrand VE, Quan C, Melamed E, Palace J, Sun J, Asgari N, Broadley SA; Guthy Jackson International Clinical Consortium.
J Neurol 271 ( 8 ) 4794 - 4812 2024.8
-
Humanized-aquaporin-4-expressing rat created by gene-editing technology and its use to clarify the pathology of neuromyelitis optica spectrum disorder.
Namatame C, Abe Y, Miyasaka Y, Takai Y, Matsumoto Y, Takahashi T, Mashimo T, Misu T, Fujihara K, Yasui M, Aoki M
Int J Mol Sci 25 ( 15 ) 8169 2024.7
-
Neuromyelitis optica spectrum disorders registry system in Iran: Validity of data sets.
Khodaie F, Mohamadi M, Ebrahimi Y, Sahraian MA, Moghadasi AN, Ayoubi S, Goudarzi H, Paybast S, Kamyari N, Asgari N, Fujihara K, Heidari H, Eskandarieh S
Mult Scler Relat Disord 87 105685 2024.7
-
Safety and efficacy of inebilizumab in patients with neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree AC, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, She D, Rees W, Smith M, Cimbora D, Katz E, Bennett JL, on behalf of the N-MOmentum study investigators.
Lancet Neurol 23 ( 6 ) 588 - 602 2024.6
-
Stochastic models for the development and disease course of multiple sclerosis.
Akaishi T, Misu T, Takahashi T, Fujihara K, Fujimori J, Nakashima I, Aoki M
Clin Neurol Neurosurg 239 108224 2024.4
-
Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database.
Nakashima I, Nakahara J, Yasunaga H, Yamashita M, Nishijima N, Satomura A, Nio M, Fujihara K
Mult Scler Relat Disord 84 105502 2024.4
-
Dynamic changes in patient admission and their disabilities in multiple sclerosis and neuromyelitis optica: a Japanese nationwide administrative data study.
Matsumoto Y, Tarasawa K, Misu T, Namatame C, Takai Y, Kuroda K, Fujihara K, Fushimi K, Fujimori K, Aoki M.
Mult Scler Relat Disord 81 105349 2024.1
-
Differential diagnosis of suspected multiple sclerosis: global health considerations.
Correale J, Solomon AJ, Cohen JA, Banwell BL, Gracia F, Gyang TV, de Bedoya FHD, Harnegie MP, Hemmer B, Jacob A, Kim HJ, Marrie RA, Mateen FJ, Newsome SD, Pandit L, Prayoonwiwat N, Sahraian MA, Sato DK, Saylor D, Shi FD, Siva A, Tan K, Viswanathan S, Wattjes M, Weinshenker B, Yamout B, Fujihara K
Lancet Neurol 23 ( 10 ) 1035 - 1049 2024.1
-
Myelin oligodendrocyte glycoprotein antibody-associated disorders: an overview.
Misu T, Matsumoto Y, Kaneko K, Takahashi T, Takai Y, Ono H, Namatame C, Nishiyama S, Fujimori J, Kuroda H, Nakashima I, Fujihara K, Aoki M.
Clin Exp Neuroimmunol. 2023.12
-
Microfibrillar-associated protein 4 as potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: pathological and clinical aspects.
Samadzadeh S, Olesen MN, Wirenfeldt M, Möller S, Misu T, Soelberg K, Frederiksen JL, Heegaard S, Mariotto S, Fujihara K, Ruprecht K, Andersen TL, Marignier R, Lillevang ST, Flanagan EP, Pittock SJ, Kim HJ, Bennett JL, Friedeman Paul F, Sorensen GL, Weinshenker BG, Lassmann H, Asgari N.
Mult Scler. 29 ( 14 ) 1721 - 1735 2023.10
-
Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
Matsumoto Y, Kaneko K, Takahashi T, Takai Y, Namatame C, Kuroda H, Misu T, Fujihara K, Aoki M.
Brain. 146 ( 9 ) 3938 - 3948 2023.9
-
Epidemiology of MOGAD: A review of prevalence and incidence worldwide.
Hor JY, Fujihara K.
Front Neurol. 15 ( 14 ) 1260358 2023.9
-
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
Aktas O, Hartung HP, Smith MA, Rees WA, Fujihara K, Paul F, Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Cutter G, She D, Gunsior M, Cimbora D, Katz E, Cree BAC, N-MOmentum study investigators.
J Neurol Neurosurg Psychiatry. 94 ( 9 ) 757 - 768 2023.9
-
Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study.
Fujihara K, Kim HJ, Saida T, Misu T, Nagano Y, Totsuka N, Iizuka M, Kido S, Terata R, Okumura K, Hirota S, Cree BAC.
Mult Scler Relat Disord. 79 104938 2023.8
-
Differential diagnosis of suspected multiple sclerosis: an updated consensus approach.
Solomon AJ, Arrambide G, Brownlee WJ, Flanagan EP, Amato MP, Amezcua L, Banwell BL, Barkhof F, Corboy JR, Correale J, Fujihara K, Graves J, Harnegie MP, Hemmer B, Lechner-Scott J, Marrie RA, Newsome SD, Rocca MA, Royal W, Waubant EL, Yamout B, Cohen JA.
Lancet Neurol. 22 ( 8 ) 750 - 768 2023.8
-
Associations between neuromyelitis optica spectrum disorder, Sjogren's ¨ syndrome, and conditions with electrolyte disturbances.
Akaishi T, Tarasawa K, Matsumoto Y, Sandhya P, Misu T, Fushimie K, Takahashi T, Fujimori J, Ishii T, Fujimori K, Yaegashi N, Nakashima I, Fujihara K, Aoki M.
J Neurol Sci. 452 120742 2023.7